Position: Research Associate in Obesity and Metabolic Diseases

Berg Biosystems is a Boston based pharma company that employs systems biology for drug discovery and development. The company uses proprietary platform technologies to understand disease targets and biomarkers. The Obesity program at Berg Biosystems is part of the Endocrinology division and is committed to the identification and validation of potential targets regulating metabolic pathways in the disease state. We have an immediate opening for a Research Associate with experience in the areas of adipocyte biology, metabolic and mitochondrial dysfunction research.

Full-time position available immediately, successful candidate will be responsible for the maintenance and differentiation of preadipocyte cell models (cell lines, primary cells) for metabolic studies. Duties include all aspects of cell culture for use in cell-based and molecular assays related to adipocyte function. In addition, oversight on ordering, sample preparation, lab maintenance is also expected with strict adherence to safety issues.

Qualifications:

- BS in biology or a related field (MS preferred) and 3-5 years (7-10 preferred) of experience in metabolic research and adipocyte biology.
- High throughput experience desired with understanding common molecular techniques that may include but are not limited to adipocyte-related functional assay, bioenergetics, real-time PCR, gene transfection, lentiviral gene delivery, Western blot, ELISA.
- Excellent communication and interpersonal skills combined with superior and proven track record of technical and organizational skills.
- Must be able to work in team-oriented environment and demonstrate attention to detail and record keeping.
- Knowledge of Microsoft Word, Excel, and PowerPoint required for preparation of reports to management. In addition, ability to prepare manuscripts for presentation, publication, and regulatory requirements is preferred.

Competitive compensation and benefit package included.

Berg Pharma is a Boston based pharmaceutical company and parent company to Berg Biosystems and Berg Diagnostics (www.bergpharma.com). Our research focus seeks to understand how alterations in metabolism relate to disease onset. We have uncovered key insight into metabolic control factors and namely into underlying elements in the
Warburg Hypothesis. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Interrogative Biology® discovery platform that translates biological output into viable therapeutics and a robust biomarker library, Berg Pharma is poised to realize its pursuit of a healthier tomorrow.

Please contact: sgesta@bergbiosystems.com with CV and cover letter.